Tourmaline Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	140.95	8.47	18.61	17.59	38.98
Short-Term Investments	62.23	0	225.36	131.9	0
Cash & Cash Equivalents	203.18	8.47	243.97	149.49	38.98
Cash Growth	2297.66%	-96.53%	63.20%	283.52%	-
Other Current Assets	5.7	-0.16	2.54	1.26	1.82
Total Current Assets	208.87	8.31	246.51	150.75	40.79
Property, Plant & Equipment	0.45	0.57	4.8	2.01	1.13
Other Long-Term Assets	0.97	0.22	0.1	0.01	0.02
Total Long-Term Assets	1.42	0.79	4.91	2.03	1.15
Total Assets	210.3	9.1	251.42	152.78	41.94
Accounts Payable	1.07	0.4	2.56	0.77	0.67
Current Debt	0.22	0.16	0	0	0
Other Current Liabilities	3.71	0.8	5.43	2.64	1.62
Total Current Liabilities	5	1.36	7.99	3.4	2.29
Long-Term Debt	0.19	0.34	0	0	0
Other Long-Term Liabilities	0.06	0	0.63	1.37	0.06
Total Long-Term Liabilities	0.25	0.34	0.63	1.37	0.06
Total Liabilities	5.25	1.71	8.61	4.77	2.35
Total Debt	0.42	0.5	0	0	0
Debt Growth	-17.66%	-	-	-	-
Retained Earnings	-62.05	-19.93	-90.85	-43.01	-20.31
Comprehensive Income	0.07	0	-0.08	-0.01	0
Shareholders' Equity	205.04	-19.73	242.81	-38.15	-17.1
Net Cash / Debt	202.76	7.97	243.97	149.49	38.98
Net Cash / Debt Growth	2444.08%	-96.73%	63.20%	283.52%	-
Net Cash Per Share	42.71	9.09	83.76	223.61	61.06
Working Capital	203.87	6.95	238.53	147.35	38.5
Book Value Per Share	43.19	-22.50	83.36	-57.06	-26.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).